1. Scrip
  2. >>Leadership

Novartis' Drug Discovery Head Jay Bradner On What NIBR Is Investing In

 
• By Jessica Merrill

NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly like a venture capitalist.

James Bradner
Novartis' NIBR President James Bradner

As the president of Novartis AG's Institute for Biomedical Research, James (Jay) Bradner oversees drug discovery and early development at the big pharma, committing resources to going after "high-hanging fruit" in some cases. He built his reputation in part from pioneering work on targeted protein degradation studying targets that are considered undruggable, and he has been an outspoken critic of industry at times for a tendency to chase after the same targets.

As Bradner said in a recent interview at NIBR's Cambridge, MA, headquarters, "I

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.